New Long-Term Data Shows Lebrikizumab Sustains Atopic Dermatitis Clearance With Less Frequent Dosing and Advances Findings from Dr. Philip Werschler of Spokane Dermatology Clinic

Long-term data from the ADjoin trial demonstrates that lebrikizumab (Ebglyss), an injectable treatment for moderate to severe atopic dermatitis, maintains skin clearance for up to 2 years with less frequent monthly dosing instead of biweekly administration. Nearly 80% of patients on monthly dosing maintained clear or almost clear skin, with 76% achieving IGA scores of 0 or 1, while maintaining a consistent safety profile.